The developed radioimmunoassay for plasma unconjugated estriol effectively tracks pregnancy progression and can identify intrauterine fetal demise.
Answers are grounded in this paper and cite their sources.
May support estriol monitoring for fetal status; leaves open prospective validation before clinical adoption.
A radioimmunoassay for the measurement of plasma unconjugated estriol (E3) is described. The hemiscuccinates of E3 were coupled to human serum albumin using carbodiimide, and the conjugates were used to immunize four ewes. One of the antisera obtained after 3 months of immunization was used in the assay procedure. Celite microcolumns were used to separate E3 from estrone and estradiol-17β. Separation of bound from free radioactive hormone was achieved by a dextran-coated charcoal suspension. The assay sensitivity was 25 pg, with a within-assay variance of 7% and a between-assay variance of 9%. Plasma E3 from 167 unselected pregnant patients showed a constant rise of the mean plasma E3 from 1.7 ± 0.2 ng/ml (se) at 16 to 18 weeks to 11.1 ± 0.7 ng/ml at term. After the 32nd week of pregnancy no level below 4 ng/ml was found. In pregnancies with intrauterine fetal demise, the plasma concentration of unconjugated E3 was below 4 ng/ml. The postpartum clearance of endogenous E3 was measured and found to fit two-compartment model with mean T½ of 22 minutes and 9 hours. A patient with molar pregnancy and three patients studied more than 5 days after fetal demise, still had E3 plasma concentrations of 0.3–0.5 ng/ml, suggesting some extra-fetal production of plasma E3.
No takes yet. Share an insight, caveat, or question.
Tulchinsky et al. (1971) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: